We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 92.12%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$2.08B
$7.51M 0.06%
128,666
– –
CFRX
52
DELISTED
ContraFect Corporation
CFRX
$7.28M 0.06%
5,057
– –
INSM icon
53
Insmed
INSM
$22.4B
$7M 0.06%
400,000
– –
MGNX icon
54
MacroGenics
MGNX
$233M
$6.76M 0.06%
363,676
– –
ASMB icon
55
Assembly Biosciences
ASMB
$498M
$6.37M 0.05%
20,833
– –
CBAY
56
DELISTED
Cymabay Therapeutics
CBAY
$6.08M 0.05%
1,413,499
+1,104,231
+357% +$3.17M
LOXO
57
DELISTED
Loxo Oncology, Inc
LOXO
$5.8M 0.05%
137,735
– –
AKTX
58
Akari Therapeutics
AKTX
$14.4M
$5.5M 0.05%
621
– –
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$5.42M 0.04%
633,497
+300,000
+90% +$2.73M
RXDX
60
DELISTED
Ignyta, Inc.
RXDX
$4.91M 0.04%
571,000
– –
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$4.52M 0.04%
217,328
– –
BIIB icon
62
Biogen
BIIB
$30.9B
$4.51M 0.04%
16,500
– –
NBRV
63
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.2M 0.03%
1,400
– –
ANAB icon
64
AnaptysBio
ANAB
$1.54B
$4.16M 0.03%
+150,000
New +$3.49M
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$4.14M 0.03%
381,939
-456,870
-54% -$4.63M
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$3.99M 0.03%
232,481
– –
RARX
67
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.79M 0.03%
177,952
– –
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.39M 0.03%
50,000
– –
SYRS
69
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.26M 0.03%
20,447
– –
TRVN
70
DELISTED
Trevena, Inc.
TRVN
$3.15M 0.03%
1,372
+652
+91% +$2.22M
VIRX
71
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.04M 0.02%
21,190
– –
ADMS
72
DELISTED
Adamas Pharmaceuticals
ADMS
$3.02M 0.02%
172,630
– –
GNMX
73
DELISTED
Aevi Genomic Medicine Inc
GNMX
$3.01M 0.02%
1,618,089
+737,550
+84% +$3.34M
KPTI icon
74
Karyopharm Therapeutics
KPTI
$155M
$2.79M 0.02%
14,466
– –
TRIL
75
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.54M 0.02%
413,697
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Baker Bros. Advisors held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Baker Bros. Advisors's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Baker Bros. Advisors added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Baker Bros. Advisors's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Baker Bros. Advisors fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Baker Bros. Advisors opened 4 new positions and closed 18 in Q1 2017.
  • Baker Bros. Advisors's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.